Related Experiment Video
Updated: May 14, 2026

Prediction and Validation of Gene Regulatory Elements Activated During Retinoic Acid Induced Embryonic Stem Cell Differentiation
Published on: June 21, 2016
ERCC1 and RRM1: ready for prime time?
Benjamin Besse1, Ken A Olaussen, Jean-Charles Soria
1Université Paris Sud, Kremlin-Bicêtre, France.
Abstract:
The quest for markers of sensitivity to cytotoxic agents has been ongoing for decades. In non-small-cell lung cancer, platinum compounds represent the cornerstone of systemic therapy. They target DNA and induce damage that cancer cells struggle to overcome. Somatic excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1), and ribonucleotide reductase M1 (RRM1) expression levels have been extensively explored as markers of DNA repair capacity in tumor cells. Although low ERCC1 and/or RRM1 expression is generally associated with sensitivity to platinum, the results published in retrospective and prospective studies are not always consistent. Against this background, we will examine in this review the function of these two biomarkers as well as the tools available for their assessment and the associated technical issues. Their prognostic and predictive values will be summarized and considered in terms of customizing systemic therapy according to biomarker (ERCC1 and RRM1) expression levels. We will also discuss why the use of both markers should at this point be restricted to clinical research and underline that functional readouts of DNA repair will help boost future strategies for biomarker discovery in the field.
Insights
Identifying reliable biomarkers for non-small-cell lung cancer (NSCLC) treatment is crucial. This review examines excision repair cross-complementing 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) expression as predictive markers for platinum-based chemotherapy in NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Biomarkers
Background:
- Platinum compounds are a primary treatment for non-small-cell lung cancer (NSCLC), targeting cancer cell DNA.
- Excision repair cross-complementing 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) are explored as markers of DNA repair capacity.
- Existing studies on ERCC1 and RRM1 expression show inconsistent associations with platinum sensitivity.
Purpose of the Study:
- To review the function and assessment methods of ERCC1 and RRM1 as biomarkers in NSCLC.
- To summarize the prognostic and predictive value of ERCC1 and RRM1 for platinum-based therapy.
- To discuss the current limitations and future directions for biomarker discovery in NSCLC.
Main Methods:
- Literature review of studies investigating ERCC1 and RRM1 expression in NSCLC.
- Analysis of methodologies used for assessing ERCC1 and RRM1 levels.
- Synthesis of data on the prognostic and predictive significance of these biomarkers.
Main Results:
- Low ERCC1 and RRM1 expression generally correlates with platinum sensitivity, but results vary across studies.
- Technical issues in biomarker assessment contribute to inconsistent findings.
- The prognostic and predictive roles of ERCC1 and RRM1 require further validation.
Conclusions:
- ERCC1 and RRM1 show potential as predictive biomarkers for platinum chemotherapy in NSCLC.
- Current inconsistencies suggest restricting their use to clinical research.
- Functional assays for DNA repair capacity may offer improved strategies for biomarker development.
Related Concept Videos
Regulation of the Unfolded Protein Response
Directing Proteins to the Rough Endoplasmic Reticulum
RACE - Rapid Amplification of cDNA Ends
Since the...
The Unfolded Protein Response
Rab Proteins
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

